| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18729 R79660 |
Moore (Topiramate) (Epilepsy) (Controls exposed to LTG), 2025 | Early childhood developmental concerns (any developmental concerns on any domain at the 27–30 month assessment offered to all children) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.98 [0.35;2.77] C excluded (control group) |
5/20 90/354 | 95 | 20 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18728 R79657 |
Moore (Topiramate) (Epilepsy) (Controls unexposed, sick), 2025 | Early childhood developmental concerns (any developmental concerns on any domain at the 27–30 month assessment offered to all children) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Matched | 1.08 [0.38;3.05] | 5/20 47/200 | 52 | 20 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12719 R47982 |
Bjørk (Topiramate) (Controls exposed to Lamotrigine, sick), 2022 | Neurodevelopmental Disorder (ND): any diagnoses of autism spectrum disorder (F84.0, F84.1, F84.5) or intellectual disability (F70, F71, F72, F73) plus F84.3, F84.4, F84.8, F84.9, F79 - Median follow up topiramate 5.7 (2.9-9.1) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
2.61 [1.34;5.10] C excluded (control group) |
10/246 81/5,073 | 91 | 246 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12720 R47985 |
Bjørk (Topiramate) (Controls unexposed NOS), 2022 | Neurodevelopmental Disorder (ND): any diagnoses of autism spectrum disorder (F84.0, F84.1, F84.5) or intellectual disability (F70, F71, F72, F73) plus F84.3, F84.4, F84.8, F84.9, F79 - Median follow up topiramate 5.7 (2.9-9.1) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: No |
2.73 [1.45;5.14] C excluded (control group) |
10/246 68,295/4,463,879 | 68,305 | 246 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12721 R47988 |
Bjørk (Topiramate) (Controls unexposed, sick), 2022 | Neurodevelopmental Disorder (ND): any diagnoses of autism spectrum disorder (F84.0, F84.1, F84.5) or intellectual disability (F70, F71, F72, F73) plus F84.3, F84.4, F84.8, F84.9, F79 - Median follow up topiramate 5.7 (2.9-9.1) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 2.13 [1.13;4.01] | 10/246 443/21,634 | 453 | 246 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6251 R16646 |
Arkilo (Topiramate), 2015 | Abnormal development (At 2 years of age, assessed by developmental specialists) | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 2.87 [0.09;91.05] C | 0/2 2/24 | 2 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 1.79 [1.05;3.06] | 507 | 268 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Topiramate) (Epilepsy) (Controls unexposed, sick; 2: Topiramate) (Controls unexposed, sick; 3: Topiramate;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 12719, 12720, 18729